SEC For	m 4 FORM	4	UNITED) STA	TES	S SI	ECUR	ITIE	ES ANI	DE	ХСНА	NGE	CON	/MI	SSION				
						Washington, D.C. 20549											OMB APPROVAL		
Section 16. Form 4 or Form 5 obligations may continue. See						Pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940									HIP	Estim		er: verage burder sponse:	3235-0287 h 0.5
1. Name and Address of Reporting Person [*] Ho Carole						2. Issuer Name and Ticker or Trading Symbol <u>Denali Therapeutics Inc.</u> [DNLI]									5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner X Officer (give title Other (spe below) below)				vner
(Last) (First) (Middle) C/O DENALI THERAPEUTICS INC. 161 OYSTER POINT BLVD.						3. Date of Earliest Transaction (Month/Day/Year) 01/04/2021								Chief Medical Officer					
(Street) SOUTH SAN FRANCISCO CA 94080					4.	4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person					
(City) (State) (Zip)																			
		Tab	ole I - Nor	n-Deriv	, ativ	e Se	curities	s Ac	quired,	Dis	posed o	of, or B	enefi	ciall	y Owned				
Date			2. Trans Date (Month/		Execution if any	A. Deemed xecution Date, any Month/Day/Year)		Code (Instr.					5. Amour Securitie Beneficia Owned F	s Forn Ily (D) o ollowing (I) (Ir		: Direct r Indirect str. 4)	7. Nature of Indirect Beneficial Ownership		
								Code	v	Amount	(A) (D)	or P	rice	Reported Transact (Instr. 3 a	ion(s)			(Instr. 4)	
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	rivative Conversion Date Execution Date curity or Exercise (Month/Day/Year) if any			Date,	ate, Transaction Code (Instr.					6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amo of Securities Underlying Derivative Secu (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Date Exercisab		Expiration Date	Title	or	ount nber ıres					

Restricted 01/04/2021 (2) (1) 30,000 (2) Stock Units A Stock Option (right to 01/04/2021 (3) \$70.86 A 90,000 01/03/2031 buy)

Explanation of Responses:

1. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer.

2. 25% of the restricted stock units shall vest on January 4, 2022 (the "Vesting Commencement Date") and an additional 25% of the restricted stock units shall vest on each annual anniversary of the Vesting Commencement Date thereafter, subject to the Reporting Person remaining a service provider of the Issuer through each such date.

3. 25% of the shares subject to the option shall vest on January 4, 2022, and 1/48 of the shares subject to the option shall vest each month thereafter, subject to the Reporting Person remaining a service provider of the Issuer through each such date.

Remarks:

<u>/s/ Tyler Nielsen, by power of attorney</u>

30.000

90,000

\$0.00

\$0.00

Common

Stock

Common Stock

01/06/2021

30,000

90,000

D

D

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.